Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2025-02-05
DOI
https://doi.org/10.1186/s12885-025-13605-2
Citations
3
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
3.97

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial

Yishen Wu, Jingjun Huang, Licong Liang, Wenbo Shi et al.
3 citations
BMC Cancer
Hepatocellular Carcinoma Treatment and Prognosis
3.97
article

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial

Yishen Wu, Jingjun Huang, Licong Liang, Wenbo Shi, Xiaoyang Hong, Kangshun Zhu, Wensou Huang, Yongjian Guo, Mingyue Cai, Jingwen Zhou, Ye Chen, Liteng Lin, J. D. Huang
article en
3 citations

Abstract

No abstract available for this paper.
BMC CancerVol. 25(1)
Shantou University (CN), Second Affiliated Hospital of Guangzhou Medical University (CN), Yue Bei People's Hospital (CN), Shanghai Sixth People's Hospital (CN), Guangzhou Medical University (CN)
Guangzhou Medical University, National Natural Science Foundation of China, Southern Medical University
Good health and well-being
Openalex Percentile: Top 7%
Hepatocellular Carcinoma Treatment and Prognosis
3.97
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.